MDS Clinical Trial Landscape
Data updated: May 20, 2026
1,170 clinical trials tracked since 2008
Myelodysplastic syndromes (MDS) are a group of related blood cancers in which the bone marrow does not produce enough healthy blood cells. MDS primarily affects older adults and can lead to anemia, infections, and bleeding. The clinical trial landscape for MDS reflects substantial research activity, with 1,157 trials registered since 2008. Currently, 383 trials are actively recruiting, enrolling, or active but not recruiting participants. The majority of active trials are in Phase 1 (188 trials) and Phase 2 (236 trials), while Phase 3 trials are less numerous (34 trials), and no Phase 4 trials are currently active. Bristol-Myers Squibb leads industry sponsorship of active trials with 6 ongoing, followed by Takeda, Taiho Oncology, Inc., and Orca Biosystems, Inc., each sponsoring 4 active trials. Bellicum Pharmaceuticals sponsors 3 active trials. The distribution of trials across phases suggests a strong focus on early-stage drug development for MDS.
387 active
/
1170 total (since 2008)
187
Phase 1 Active
580 total
242
Phase 2 Active
704 total
35
Phase 3 Active
94 total
0
Phase 4 Active
10 total
Top Industry Sponsors
Sorted by active Active Done Failed
Bristol-Myers Squibb 6 15 5
Takeda 4 2 1
Taiho Oncology, Inc. 4 1 0
Orca Biosystems, Inc. 4 0 0
Bellicum Pharmaceuticals 3 0 5
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06499285 RECRUITING
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda n=225
NCT06465953 RECRUITING
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier n=48
NCT04401748 ACTIVE NOT RECRUITING
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie n=531
NCT04217278 ACTIVE NOT RECRUITING
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
University of Birmingham n=333
NCT05949684 ACTIVE NOT RECRUITING
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Bristol-Myers Squibb n=360
+ 89 more Phase 3 trials — see full database below
MDS — Trials Started by Year (last 10 years)
2016 60
2017 61
2018 67
2019 67
2020 64
2021 74
2022 62
2023 46
2024 59
2025 69
2026 37
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Bristol-Myers Squibb 26
Takeda 7
Taiho Oncology, Inc. 5
Orca Biosystems, Inc. 4
Bellicum Pharmaceuticals 8
Novartis 23
AbbVie 4
GCP-Service International West GmbH 2
Ascentage Pharma Group Inc. 2
Ryvu Therapeutics SA 2
Active Trials by Phase
Phase 1 187
Phase 2 242
Phase 3 35
Enrollment Size Distribution
1-50 691
51-200 333
201-500 74
501-1k 14
1k+ 3
All Industry Sponsors
Sorted by active Active Done Failed
Bristol-Myers Squibb 6 15 5
Takeda 4 2 1
Taiho Oncology, Inc. 4 1 0
Orca Biosystems, Inc. 4 0 0
Bellicum Pharmaceuticals 3 0 5
Novartis 2 9 12
AbbVie 2 1 1
GCP-Service International West GmbH 2 0 0
Ascentage Pharma Group Inc. 2 0 0
Ryvu Therapeutics SA 2 0 0
Akeso 2 0 0
Johnson & Johnson 1 4 2
Sumitomo Pharma America, Inc. 1 1 2
Celyad Oncology SA 1 2 1
GSK 1 1 1
NCT06499285 RECRUITING
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda n=225
NCT06465953 RECRUITING
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier n=48
NCT04401748 ACTIVE NOT RECRUITING
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie n=531
NCT04217278 ACTIVE NOT RECRUITING
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
University of Birmingham n=333
NCT05949684 ACTIVE NOT RECRUITING
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Bristol-Myers Squibb n=360
NCT00843882 ACTIVE NOT RECRUITING
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI) n=247
NCT04256317 RECRUITING
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc. n=316
NCT04547049 ACTIVE NOT RECRUITING
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
First Affiliated Hospital of Zhejiang University n=232
NCT07396480 RECRUITING
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
First Affiliated Hospital of Zhejiang University n=186
NCT07422480 RECRUITING
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda n=300
NCT05316701 ACTIVE NOT RECRUITING
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc. n=187
NCT05469737 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Bristol-Myers Squibb n=230
NCT04708054 RECRUITING
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center n=324
NCT02598661 ACTIVE NOT RECRUITING
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation n=289
NCT05457556 ACTIVE NOT RECRUITING
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group n=435
NCT06641414 RECRUITING
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Ascentage Pharma Group Inc. n=490
NCT04064060 RECRUITING
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene n=665
NCT06045689 ACTIVE NOT RECRUITING
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Bristol-Myers Squibb n=106
NCT03173248 ACTIVE NOT RECRUITING
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier n=146
NCT05181592 ACTIVE NOT RECRUITING
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
GWT-TUD GmbH n=70
NCT02521493 ACTIVE NOT RECRUITING
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group n=280
NCT06972641 RECRUITING
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital n=126
NCT04184505 RECRUITING
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Gruppo Italiano Malattie EMatologiche dell'Adulto n=274
NCT06927232 NOT YET RECRUITING
AZA+Lus VS AZA Monotherapy in HR-MDS
Peking Union Medical College Hospital n=86
NCT05883956 ACTIVE NOT RECRUITING
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Otsuka Australia Pharmaceutical Pty Ltd n=13
NCT03223961 ACTIVE NOT RECRUITING
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies n=124
NCT05991908 RECRUITING
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine n=222
NCT05674539 ENROLLING BY INVITATION
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=200
NCT06756152 RECRUITING
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=50
NCT05153226 ACTIVE NOT RECRUITING
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
DKMS gemeinnützige GmbH n=640
NCT04027309 ACTIVE NOT RECRUITING
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=777
NCT03682536 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Celgene n=363
NCT03839771 ACTIVE NOT RECRUITING
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=968
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT05515029 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=56
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT01366612 TERMINATED
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Hackensack Meridian Health n=53
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04266301 TERMINATED
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Novartis Pharmaceuticals n=530
NCT03594149 COMPLETED
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Centre Henri Becquerel n=60
NCT03268954 COMPLETED
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Takeda n=454
NCT05709093 TERMINATED
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd. n=10
NCT04797780 TERMINATED
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Syros Pharmaceuticals n=246
NCT03016130 TERMINATED
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
University of Florida n=217
NCT03745716 COMPLETED
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics n=154
NCT01196715 COMPLETED
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
Barts & The London NHS Trust n=360
NCT03092674 COMPLETED
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI) n=76
NCT01566695 COMPLETED
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Celgene n=216
NCT02085408 COMPLETED
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
ECOG-ACRIN Cancer Research Group n=727
NCT02907359 COMPLETED
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc. n=417
NCT03306264 COMPLETED
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc. n=227
NCT03275636 COMPLETED
Haploidentical Donor vs mMUD in Hematological Malignancies
DKMS gemeinnützige GmbH n=98
NCT03263091 TERMINATED
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Kyntra Bio n=184
NCT04313881 TERMINATED
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Gilead Sciences n=539
NCT04842604 COMPLETED
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer n=14
NCT01288378 COMPLETED
Empirical Versus Preemptive Antifungal Therapy
European Organisation for Research and Treatment of Cancer - EORTC n=556
NCT03699475 TERMINATED
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Bellicum Pharmaceuticals n=1
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT03303066 COMPLETED
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
Kyntra Bio n=43
NCT02942173 COMPLETED
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT04326764 TERMINATED
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University n=52
NCT01243476 COMPLETED
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Fundación General de la Universidad de Salamanca n=61
NCT04095858 TERMINATED
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=11
NCT02562443 TERMINATED
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Traws Pharma, Inc. n=372
NCT02999854 TERMINATED
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Kiadis Pharma n=63
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT02744742 COMPLETED
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University n=202
NCT02631070 COMPLETED
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Celgene n=229
NCT02214407 COMPLETED
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
Groupe Francophone des Myelodysplasies n=170
NCT00967343 TERMINATED
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma n=40
NCT03066466 WITHDRAWN
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
NCT01602211 COMPLETED
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant
Fred Hutchinson Cancer Center n=1,600
NCT00822393 COMPLETED
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH n=570
NCT00750009 COMPLETED
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center n=583
NCT01241500 COMPLETED
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Traws Pharma, Inc. n=299
NCT01928537 COMPLETED
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc. n=67
NCT00887068 COMPLETED
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
M.D. Anderson Cancer Center n=187
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT02008318 COMPLETED
A Study of Galunisertib in Participants With Myelodysplastic Syndromes
Eli Lilly and Company n=43
NCT01295710 COMPLETED
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech n=260
NCT00656448 COMPLETED
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
M.D. Anderson Cancer Center n=51
NCT01362140 COMPLETED
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Amgen n=147
NCT00516503 COMPLETED
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology n=208
NCT00755040 COMPLETED
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center n=164
NCT01749111 TERMINATED
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
Hospital Israelita Albert Einstein n=3
NCT00719563 COMPLETED
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology n=364
NCT01751867 COMPLETED
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
Xian-Janssen Pharmaceutical Ltd. n=135
NCT01381809 COMPLETED
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Janssen-Cilag International NV n=130
NCT01188798 COMPLETED
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital n=6
NCT00695396 TERMINATED
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. n=25
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT00782145 COMPLETED
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center n=198
NCT07463820 NOT YET RECRUITING
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05564390 RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
NCT05600894 ACTIVE NOT RECRUITING
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
NCT05320198 RECRUITING
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
NCT03520647 RECRUITING
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
National Heart, Lung, and Blood Institute (NHLBI)
NCT06577441 RECRUITING
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07153497 NOT YET RECRUITING
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
NCT06303193 RECRUITING
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Cancer Institute (NCI)
NCT07579429 NOT YET RECRUITING
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
University of Colorado, Denver
NCT07582172 NOT YET RECRUITING
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
NCT05583552 ACTIVE NOT RECRUITING
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
GCP-Service International West GmbH
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT07575412 NOT YET RECRUITING
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
NCT01861106 RECRUITING
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
National Cancer Institute (NCI)
NCT07572929 NOT YET RECRUITING
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Medical College of Wisconsin
NCT05092451 RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT04872595 ACTIVE NOT RECRUITING
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Memorial Sloan Kettering Cancer Center
NCT07566377 RECRUITING
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT05732961 ACTIVE NOT RECRUITING
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT04726241 RECRUITING
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
NCT04493138 ACTIVE NOT RECRUITING
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
NCT06113302 RECRUITING
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
NCT03670966 RECRUITING
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT07562568 NOT YET RECRUITING
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
NCT01522976 ACTIVE NOT RECRUITING
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT07549451 NOT YET RECRUITING
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
NCT05998408 RECRUITING
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
National Heart, Lung, and Blood Institute (NHLBI)
NCT04128748 RECRUITING
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07155226 RECRUITING
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
AstraZeneca
NCT05490446 ACTIVE NOT RECRUITING
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Agios Pharmaceuticals, Inc.
NCT06923488 RECRUITING
Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
West Virginia University
NCT03164057 ACTIVE NOT RECRUITING
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT05428969 ACTIVE NOT RECRUITING
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Faron Pharmaceuticals Ltd
NCT07528417 NOT YET RECRUITING
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
University of Manitoba
NCT06599762 RECRUITING
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
University of Manitoba
NCT06847867 RECRUITING
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
GlaxoSmithKline
NCT04061421 RECRUITING
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Michael Savona
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07052006 ACTIVE NOT RECRUITING
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
Halia Therapeutics, Inc.
NCT05177211 ACTIVE NOT RECRUITING
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
NCT07493538 RECRUITING
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT07532824 RECRUITING
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Institute of Hematology and Blood Transfusion, Czech Republic
NCT05285813 ACTIVE NOT RECRUITING
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT02250937 ACTIVE NOT RECRUITING
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT06839456 RECRUITING
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT07216443 RECRUITING
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
NCT07400341 RECRUITING
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
The First Affiliated Hospital of Soochow University
NCT01624805 RECRUITING
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT02392572 RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03953898 ACTIVE NOT RECRUITING
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
National Cancer Institute (NCI)
NCT04214249 ACTIVE NOT RECRUITING
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05732103 RECRUITING
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Chordia Therapeutics, Inc.
NCT04239157 RECRUITING
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT03289910 ACTIVE NOT RECRUITING
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT05554419 NOT YET RECRUITING
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04284787 ACTIVE NOT RECRUITING
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02944955 NOT YET RECRUITING
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
BioLite, Inc.
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT07516847 NOT YET RECRUITING
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
Seug yun Yoon, MD
NCT05483010 RECRUITING
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
Washington University School of Medicine
NCT04187105 RECRUITING
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
University of Illinois at Chicago
NCT03173937 RECRUITING
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
National Heart, Lung, and Blood Institute (NHLBI)
NCT04734990 ACTIVE NOT RECRUITING
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT06063486 RECRUITING
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
NCT04988555 RECRUITING
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
NCT04742634 RECRUITING
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
NCT04797000 ACTIVE NOT RECRUITING
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
Novartis Pharmaceuticals
NCT05796570 RECRUITING
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT06859424 RECRUITING
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT07387354 NOT YET RECRUITING
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Thomas Jefferson University
NCT04282187 RECRUITING
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04644016 RECRUITING
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT05782127 ACTIVE NOT RECRUITING
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT05379166 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Uma Borate
NCT03970096 RECRUITING
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT05226455 ACTIVE NOT RECRUITING
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Groupe Francophone des Myelodysplasies
NCT03862157 ACTIVE NOT RECRUITING
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03471260 RECRUITING
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06548230 RECRUITING
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
NCT05181735 RECRUITING
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Groupe Francophone des Myelodysplasies
NCT03214562 RECRUITING
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02530463 ACTIVE NOT RECRUITING
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03683433 RECRUITING
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
NCT06566742 RECRUITING
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
M.D. Anderson Cancer Center
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT06904482 RECRUITING
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT06304103 RECRUITING
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Kind Pharmaceuticals LLC
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT03672539 ACTIVE NOT RECRUITING
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05010122 RECRUITING
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04655755 ACTIVE NOT RECRUITING
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT03383575 RECRUITING
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04761770 ACTIVE NOT RECRUITING
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04419649 RECRUITING
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Takeda
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT03579875 RECRUITING
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Masonic Cancer Center, University of Minnesota
NCT06091267 ACTIVE NOT RECRUITING
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Otsuka Beijing Research Institute
NCT07046078 RECRUITING
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center
NCT02935361 ACTIVE NOT RECRUITING
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
NCT04262843 ACTIVE NOT RECRUITING
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT03842696 ACTIVE NOT RECRUITING
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT04994808 ACTIVE NOT RECRUITING
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT07228273 RECRUITING
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT03121014 ACTIVE NOT RECRUITING
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
University of Illinois at Chicago
NCT04550442 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT03661307 RECRUITING
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT01174108 RECRUITING
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
National Heart, Lung, and Blood Institute (NHLBI)
NCT05201066 ACTIVE NOT RECRUITING
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis Pharmaceuticals
NCT01746849 ACTIVE NOT RECRUITING
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT07319845 NOT YET RECRUITING
A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Takeda
NCT05184842 RECRUITING
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Montefiore Medical Center
NCT05365035 RECRUITING
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
M.D. Anderson Cancer Center
NCT07301866 RECRUITING
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Ciusss de L'Est de l'Île de Montréal
NCT04269213 ACTIVE NOT RECRUITING
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Roswell Park Cancer Institute
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT04802161 ACTIVE NOT RECRUITING
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
NCT03128034 RECRUITING
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT04068597 RECRUITING
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04047641 RECRUITING
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03564873 ACTIVE NOT RECRUITING
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
University of Colorado, Denver
NCT06680752 RECRUITING
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics, Inc.
NCT05194397 RECRUITING
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT03300492 RECRUITING
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
University Hospital, Basel, Switzerland
NCT03330821 ACTIVE NOT RECRUITING
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
University of Southern California
NCT07238686 RECRUITING
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Beijing 302 Hospital
NCT04493164 RECRUITING
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03589729 RECRUITING
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
NCT07238712 RECRUITING
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT01885689 ACTIVE NOT RECRUITING
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
City of Hope Medical Center
NCT02143830 RECRUITING
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Children's Hospital Medical Center, Cincinnati
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT06928662 RECRUITING
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT02115295 RECRUITING
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04798339 ACTIVE NOT RECRUITING
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
H. Lee Moffitt Cancer Center and Research Institute
NCT06128070 RECRUITING
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT04093570 ENROLLING BY INVITATION
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc.
NCT05308264 RECRUITING
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Rigel Pharmaceuticals
NCT03779854 RECRUITING
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT06529731 RECRUITING
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD
NCT07214064 NOT YET RECRUITING
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
University Hospital Tuebingen
NCT06315309 RECRUITING
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT06265584 RECRUITING
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT05211570 RECRUITING
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AB Science
NCT05693909 RECRUITING
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Pharmacosmos A/S
NCT06704152 RECRUITING
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
NCT06918834 RECRUITING
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT07025824 NOT YET RECRUITING
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Technische Universität Dresden
NCT03399773 ACTIVE NOT RECRUITING
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT03850574 RECRUITING
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences Inc.
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT06984536 RECRUITING
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Peking University People's Hospital
NCT04668885 ACTIVE NOT RECRUITING
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Case Comprehensive Cancer Center
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT06630221 RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Abhay Singh, MD MPH
NCT06717958 RECRUITING
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Technische Universität Dresden
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT06199557 RECRUITING
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
Haukeland University Hospital
NCT06815003 RECRUITING
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06802315 RECRUITING
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT01985061 ACTIVE NOT RECRUITING
Evaluation of 3 Different Doses of IV Busulfan
Institut Paoli-Calmettes
NCT06793410 RECRUITING
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
NCT06130579 RECRUITING
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
NCT05364762 ACTIVE NOT RECRUITING
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT06243458 ACTIVE NOT RECRUITING
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
GCP-Service International West GmbH
NCT03744390 ACTIVE NOT RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT03503409 ACTIVE NOT RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT04730258 ACTIVE NOT RECRUITING
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics, Inc
NCT06268574 ACTIVE NOT RECRUITING
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Ryvu Therapeutics SA
NCT02646839 ENROLLING BY INVITATION
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Michael Pulsipher
NCT04861207 ACTIVE NOT RECRUITING
Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04232241 ACTIVE NOT RECRUITING
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Universitätsklinikum Hamburg-Eppendorf
NCT06355583 RECRUITING
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Imperial College London
NCT06156579 RECRUITING
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
University Hospital Tuebingen
NCT06900088 NOT YET RECRUITING
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT06892223 RECRUITING
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
NCT04900350 ACTIVE NOT RECRUITING
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
Akeso
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT06196203 RECRUITING
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Akeso
NCT05601726 RECRUITING
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Advanced BioDesign
NCT06765928 NOT YET RECRUITING
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
Ruijin Hospital
NCT06612944 RECRUITING
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT05924100 RECRUITING
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
Associazione Qol-one
NCT06664970 ENROLLING BY INVITATION
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Peking Union Medical College Hospital
NCT06471946 RECRUITING
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Navy General Hospital, Beijing
NCT06598969 NOT YET RECRUITING
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT06602323 NOT YET RECRUITING
TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT06594965 NOT YET RECRUITING
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Hansoh BioMedical R&D Company
NCT06536959 RECRUITING
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
NCT06532084 RECRUITING
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT06477549 RECRUITING
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT02061800 ACTIVE NOT RECRUITING
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT05807932 RECRUITING
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf
NCT06206174 RECRUITING
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.
NCT05925504 RECRUITING
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Institute of Hematology & Blood Diseases Hospital, China
NCT06046313 RECRUITING
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
First Affiliated Hospital of Zhejiang University
NCT06050941 NOT YET RECRUITING
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
NCT05384691 RECRUITING
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
University of Leipzig
NCT06235398 NOT YET RECRUITING
Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial
Assistance Publique - Hôpitaux de Paris
NCT05788679 RECRUITING
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Karolinska University Hospital
NCT04061239 RECRUITING
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
GWT-TUD GmbH
NCT06020833 NOT YET RECRUITING
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Peking Union Medical College Hospital
NCT05817955 RECRUITING
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
The First Affiliated Hospital with Nanjing Medical University
NCT04935684 RECRUITING
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT05584761 RECRUITING
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
The First Affiliated Hospital with Nanjing Medical University
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT01744223 ACTIVE NOT RECRUITING
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03301168 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT02912208 ACTIVE NOT RECRUITING
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
Associazione Qol-one
NCT05025098 RECRUITING
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
University Hospital, Akershus
NCT03886662 RECRUITING
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Lixte Biotechnology Holdings, Inc.
NCT07591168 NOT YET RECRUITING
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07582991 COMPLETED
Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Liu Tian
NCT04806906 COMPLETED
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
University of Florence
NCT04477850 COMPLETED
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Celgene
NCT03184935 SUSPENDED
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
Sclnow Biotechnology Co., Ltd.
NCT06597734 WITHDRAWN
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT01384513 COMPLETED
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03502668 COMPLETED
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Taiho Oncology, Inc.
NCT03150004 TERMINATED
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
NCT06563804 TERMINATED
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier Bio-Innovation LLC
NCT04339101 COMPLETED
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
City of Hope Medical Center
NCT04278768 SUSPENDED
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
NCT03404193 TERMINATED
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02286726 COMPLETED
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04620681 COMPLETED
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
H. Lee Moffitt Cancer Center and Research Institute
NCT06284460 WITHDRAWN
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
NCT04160052 TERMINATED
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03946670 TERMINATED
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Novartis Pharmaceuticals
NCT05120570 COMPLETED
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
NCT05115630 COMPLETED
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05086315 TERMINATED
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT01869114 COMPLETED
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05918055 TERMINATED
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT02684162 COMPLETED
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04874194 TERMINATED
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
NCT01760655 COMPLETED
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05568225 TERMINATED
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Forma Therapeutics, Inc.
NCT04582539 TERMINATED
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Incyte Corporation
NCT04878432 TERMINATED
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Novartis Pharmaceuticals
NCT04812548 TERMINATED
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
Novartis Pharmaceuticals
NCT02158858 COMPLETED
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
NCT05358808 TERMINATED
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
TC Biopharm
NCT02356159 COMPLETED
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT02438761 TERMINATED
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Institut Curie
NCT01660607 COMPLETED
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
NCT02793544 COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04539236 SUSPENDED
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Mikkael Sekeres, MD
NCT04849910 TERMINATED
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
NCT02131597 COMPLETED
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT02719574 COMPLETED
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT05024994 COMPLETED
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT00674479 COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT02397720 COMPLETED
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT01350258 TERMINATED
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04752163 TERMINATED
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04827719 COMPLETED
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Groupe Francophone des Myelodysplasies
NCT01350245 COMPLETED
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04857645 COMPLETED
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Groupe Francophone des Myelodysplasies
NCT00699842 TERMINATED
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04487106 COMPLETED
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT05766514 WITHDRAWN
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
NCT02658487 COMPLETED
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT01892371 COMPLETED
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02193958 COMPLETED
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT02649790 COMPLETED
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
NCT03931291 COMPLETED
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
NCT03011034 COMPLETED
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Janssen Research & Development, LLC
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01261312 COMPLETED
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Astex Pharmaceuticals, Inc.
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT03318159 COMPLETED
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
Seoul National University Hospital
NCT02488408 COMPLETED
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
BerGenBio ASA
NCT02807558 COMPLETED
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
NCT03486353 WITHDRAWN
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT04079296 COMPLETED
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Astellas Pharma Global Development, Inc.
NCT04762875 TERMINATED
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
NCT03238248 COMPLETED
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
NCT02532231 COMPLETED
Nivolumab in AML in Remission at High Risk for Relapse
M.D. Anderson Cancer Center
NCT03941769 COMPLETED
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
NCT04151706 COMPLETED
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT01902381 TERMINATED
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Wake Forest University Health Sciences
NCT03900715 COMPLETED
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Celgene
NCT04943757 COMPLETED
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
St. Petersburg State Pavlov Medical University
NCT02281084 COMPLETED
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Celgene
NCT05835011 TERMINATED
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Astex Pharmaceuticals, Inc.
NCT04522895 COMPLETED
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Heinrich-Heine University, Duesseldorf
NCT02103478 COMPLETED
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Astex Pharmaceuticals, Inc.
NCT03957876 TERMINATED
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
Case Comprehensive Cancer Center
NCT05178342 TERMINATED
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
University of Leipzig
NCT02268383 COMPLETED
Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
NCT02626715 COMPLETED
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Randy Windreich
NCT03176277 TERMINATED
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co., Ltd.
NCT03088709 TERMINATED
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT06337331 WITHDRAWN
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Northside Hospital, Inc.
NCT03493646 COMPLETED
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
NCT04526288 TERMINATED
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
NCT01995578 COMPLETED
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Memorial Sloan Kettering Cancer Center
NCT03175978 TERMINATED
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
IGF Oncology, LLC
NCT03047993 COMPLETED
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04942730 COMPLETED
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
St. Petersburg State Pavlov Medical University
NCT05237713 TERMINATED
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
University of Leipzig
NCT01597219 COMPLETED
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
University College, London
NCT05895201 WITHDRAWN
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
NCT04691141 TERMINATED
A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Shanghai Antengene Corporation Limited
NCT04202003 COMPLETED
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd.
NCT05367401 WITHDRAWN
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis Pharmaceuticals
NCT01892644 WITHDRAWN
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Haukeland University Hospital
NCT03433781 COMPLETED
A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
NYU Langone Health
NCT01858740 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
NCT01081431 COMPLETED
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT01812252 COMPLETED
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT02508324 TERMINATED
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
NCT05168904 SUSPENDED
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
NCT01904136 COMPLETED
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT03734601 COMPLETED
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT05201183 WITHDRAWN
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT02509546 COMPLETED
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT03961919 COMPLETED
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
Ciceri Fabio
NCT00961064 COMPLETED
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)
NCT04623996 TERMINATED
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
Sumitomo Pharma America, Inc.
NCT03593915 TERMINATED
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT01823198 COMPLETED
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
NCT04055844 COMPLETED
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
NCT02989844 COMPLETED
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Masonic Cancer Center, University of Minnesota
NCT01404741 COMPLETED
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
Universitätsklinikum Hamburg-Eppendorf
NCT02221310 COMPLETED
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
NCT02969980 COMPLETED
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
Asan Medical Center
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT02743611 TERMINATED
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
NCT02065869 TERMINATED
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03733249 TERMINATED
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT03067571 TERMINATED
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT01696461 COMPLETED
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
NCT01044745 TERMINATED
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
NCT04712942 COMPLETED
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
NCT02335268 COMPLETED
Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT00816413 WITHDRAWN
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
NCT03030612 COMPLETED
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
OncoVerity, Inc.
NCT01772420 COMPLETED
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Albert Einstein College of Medicine
NCT02842827 COMPLETED
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
NCT02728050 COMPLETED
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
NCT01572662 COMPLETED
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
NCT03417154 COMPLETED
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Masonic Cancer Center, University of Minnesota
NCT04631211 TERMINATED
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
NCT04146038 COMPLETED
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT02016781 COMPLETED
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
Medical College of Wisconsin
NCT01238211 COMPLETED
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02775903 COMPLETED
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
NCT01420926 COMPLETED
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00796068 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
NCT02743351 COMPLETED
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT02431351 WITHDRAWN
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Karyopharm Therapeutics Inc
NCT01028716 TERMINATED
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT00739141 COMPLETED
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Memorial Sloan Kettering Cancer Center
NCT04866056 TERMINATED
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT03920657 TERMINATED
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Fondazione Italiana Sindromi Mielodisplastiche-ETS
NCT03214666 TERMINATED
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
NCT00614523 COMPLETED
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Amgen
NCT03140280 COMPLETED
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
Ehab L Atallah
NCT02556931 COMPLETED
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05246384 WITHDRAWN
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Rhizen Pharmaceuticals SA
NCT01736683 COMPLETED
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
NCT01700673 COMPLETED
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02985190 COMPLETED
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
Groupe Francophone des Myelodysplasies
NCT02065154 COMPLETED
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
University of Alabama at Birmingham
NCT02610777 COMPLETED
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Millennium Pharmaceuticals, Inc.
NCT01682226 COMPLETED
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Memorial Sloan Kettering Cancer Center
NCT01119066 COMPLETED
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
NCT01168219 COMPLETED
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT03434704 COMPLETED
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
Ciceri Fabio
NCT02758223 COMPLETED
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT
Wuerzburg University Hospital
NCT04273802 COMPLETED
CPX-351 in Higher Risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT04264806 WITHDRAWN
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
NCT00968864 TERMINATED
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
NCT02436252 COMPLETED
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Sumitomo Pharma Co., Ltd.
NCT03600909 TERMINATED
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
NCT04893915 WITHDRAWN
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
NCT02228525 COMPLETED
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center
NCT03151304 TERMINATED
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
Helsinn Healthcare SA
NCT04109690 WITHDRAWN
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Yale University
NCT03072043 COMPLETED
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT04044209 WITHDRAWN
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
NCT00604201 COMPLETED
Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
NCT01305460 COMPLETED
Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)
Groupe Francophone des Myelodysplasies
NCT03824080 COMPLETED
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
NCT02795520 TERMINATED
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT00594230 TERMINATED
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
SCRI Development Innovations, LLC
NCT01462578 COMPLETED
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
Technische Universität Dresden
NCT02756572 COMPLETED
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
NCT01620216 TERMINATED
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
NCT03019939 COMPLETED
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
M.D. Anderson Cancer Center
NCT02464657 COMPLETED
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT04985656 WITHDRAWN
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Takeda
NCT00629798 COMPLETED
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
NCT02497404 COMPLETED
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Weill Medical College of Cornell University
NCT02169791 COMPLETED
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
NCT03397173 COMPLETED
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
NCT01221857 COMPLETED
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
NCT01690520 COMPLETED
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Nohla Therapeutics, Inc.
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT02424968 COMPLETED
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT04395092 WITHDRAWN
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Kiadis Pharma
NCT00860574 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT01904682 COMPLETED
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Traws Pharma, Inc.
NCT01926587 COMPLETED
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
NCT01842646 COMPLETED
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
NCT02190695 COMPLETED
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
NCT02500550 COMPLETED
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT03466320 COMPLETED
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT03929211 WITHDRAWN
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
Wake Forest University Health Sciences
NCT01794299 COMPLETED
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT02648932 TERMINATED
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
University of Chicago
NCT01338987 COMPLETED
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Cancer Institute (NCI)
NCT03113071 TERMINATED
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
NCT01930162 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Novartis Pharmaceuticals
NCT01474681 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis Pharmaceuticals
NCT02462252 COMPLETED
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
BioLineRx, Ltd.
NCT00831766 COMPLETED
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
NCT02240706 TERMINATED
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Boehringer Ingelheim
NCT01249820 COMPLETED
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease
Radboud University Medical Center
NCT00940602 COMPLETED
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Novartis Pharmaceuticals
NCT01379274 TERMINATED
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes
Rush University Medical Center
NCT03338348 COMPLETED
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
University of Ulm
NCT02953561 TERMINATED
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT01816230 COMPLETED
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
NCT02458235 COMPLETED
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT00914940 TERMINATED
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
NCT01885897 COMPLETED
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
NCT00946647 COMPLETED
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis Pharmaceuticals
NCT01235572 COMPLETED
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
Fred Hutchinson Cancer Center
NCT03059615 WITHDRAWN
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Immune System Key Ltd
NCT01866839 COMPLETED
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Heart, Lung, and Blood Institute (NHLBI)
NCT04013880 WITHDRAWN
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT02943668 TERMINATED
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03718143 TERMINATED
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
NCT02923986 WITHDRAWN
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
NCT02472691 COMPLETED
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
Heinrich-Heine University, Duesseldorf
NCT02038153 TERMINATED
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Albert Einstein College of Medicine
NCT01370213 COMPLETED
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
NCT02333058 COMPLETED
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
NCT02921061 COMPLETED
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT00923364 COMPLETED
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
National Cancer Institute (NCI)
NCT00789776 COMPLETED
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT02044796 COMPLETED
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT01664897 COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT00723099 COMPLETED
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01133275 COMPLETED
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
H. Lee Moffitt Cancer Center and Research Institute
NCT02017457 COMPLETED
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
Carlos Graux, MD, PhD
NCT01251575 COMPLETED
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01707004 COMPLETED
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
NCT01012492 COMPLETED
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Boston Children's Hospital
NCT00840827 TERMINATED
Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes
Weill Medical College of Cornell University
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT01747499 TERMINATED
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Washington University School of Medicine
NCT01529827 COMPLETED
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT02399917 TERMINATED
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02666950 COMPLETED
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
NCT02053545 WITHDRAWN
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
NCT01839916 COMPLETED
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT02447666 COMPLETED
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Celgene
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT01748240 TERMINATED
Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure
Groupe Francophone des Myelodysplasies
NCT01593670 COMPLETED
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Masonic Cancer Center, University of Minnesota
NCT02929498 TERMINATED
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
GlaxoSmithKline
NCT01392989 COMPLETED
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Everett Meyer
NCT00397579 COMPLETED
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
University of Texas Southwestern Medical Center
NCT03146871 TERMINATED
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
University of Southern California
NCT03259516 TERMINATED
Nivolumab With Chemotherapy in Refractory MDS
St. Petersburg State Pavlov Medical University
NCT02627573 TERMINATED
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
NCT01116232 TERMINATED
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
NCT02418000 TERMINATED
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
Spirita Oncology, LLC
NCT01599325 COMPLETED
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
Celgene
NCT00796562 COMPLETED
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01175785 COMPLETED
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics, Inc.
NCT01165996 COMPLETED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Case Comprehensive Cancer Center
NCT01980056 COMPLETED
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Weill Medical College of Cornell University
NCT02706899 TERMINATED
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Seagen Inc.
NCT01729845 COMPLETED
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT02296242 COMPLETED
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
BioMed Valley Discoveries, Inc
NCT02363491 COMPLETED
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Opsona Therapeutics Ltd.
NCT03337451 COMPLETED
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Opsona Therapeutics Ltd.
NCT00655395 TERMINATED
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Viron Therapeutics Inc
NCT02019069 COMPLETED
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Rondeep Brar
NCT01479582 WITHDRAWN
Providing Access to Cord Blood Units for Transplants
National Cancer Institute (NCI)
NCT02197676 COMPLETED
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Groupe Francophone des Myelodysplasies
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01835587 COMPLETED
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Celgene
NCT00903760 COMPLETED
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
NCT03365661 WITHDRAWN
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Masonic Cancer Center, University of Minnesota
NCT00709592 COMPLETED
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
NCT02477631 COMPLETED
Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
Sheba Medical Center
NCT01868477 COMPLETED
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Novartis Pharmaceuticals
NCT02992860 TERMINATED
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
GWT-TUD GmbH
NCT00867308 TERMINATED
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02732184 COMPLETED
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Aeglea Biotherapeutics
NCT01687400 COMPLETED
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Washington University School of Medicine
NCT02550535 COMPLETED
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Cell Medica Ltd
NCT01846624 TERMINATED
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
David Iberri
NCT02928419 TERMINATED
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Associazione Qol-one
NCT01873703 COMPLETED
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
Helsinn Healthcare SA
NCT01273766 COMPLETED
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT00939159 TERMINATED
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT02663752 TERMINATED
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Novartis Pharmaceuticals
NCT00795002 COMPLETED
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01795924 TERMINATED
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Biosuccess Biotech Co., Ltd.
NCT01789255 COMPLETED
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
NCT01745913 TERMINATED
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
NCT00987480 COMPLETED
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Memorial Sloan Kettering Cancer Center
NCT01517035 COMPLETED
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01135329 TERMINATED
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01050764 TERMINATED
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Everett Meyer
NCT02452346 COMPLETED
Study of Clinical Efficacy and Safety of Tosedostat in MDS
Weill Medical College of Cornell University
NCT00830518 COMPLETED
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Millennium Pharmaceuticals, Inc.
NCT02877082 TERMINATED
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
NCT02038816 TERMINATED
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
Sunnybrook Health Sciences Centre
NCT02204020 WITHDRAWN
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
University of Pittsburgh
NCT02269579 WITHDRAWN
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
NCT02198482 TERMINATED
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
University of Ulm
NCT01491958 COMPLETED
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
NCT02093429 TERMINATED
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
Incyte Corporation
NCT02294552 COMPLETED
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Ivan S Moiseev
NCT01564277 TERMINATED
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT01442714 TERMINATED
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
NCT00963872 TERMINATED
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00818649 TERMINATED
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
NCT01088373 COMPLETED
Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
Groupe Francophone des Myelodysplasies
NCT02238925 COMPLETED
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Jazz Pharmaceuticals
NCT02433483 TERMINATED
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
NCT01101880 COMPLETED
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
NCT02018926 COMPLETED
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Mirati Therapeutics Inc.
NCT01141725 COMPLETED
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Fred Hutchinson Cancer Center
NCT01034657 TERMINATED
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
Novartis Pharmaceuticals
NCT01349972 COMPLETED
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00863148 COMPLETED
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
Nantes University Hospital
NCT01643668 COMPLETED
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT00839982 COMPLETED
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT00691015 COMPLETED
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
NCT00607997 COMPLETED
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
NCT00906334 COMPLETED
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Traws Pharma, Inc.
NCT00854945 COMPLETED
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma, Inc.
NCT01584531 COMPLETED
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Traws Pharma, Inc.
NCT00867061 WITHDRAWN
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
NCT00744536 COMPLETED
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
Sunnybrook Health Sciences Centre
NCT01305135 COMPLETED
Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT01158118 COMPLETED
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
NCT02829840 WITHDRAWN
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT01323920 COMPLETED
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
NCT00448201 COMPLETED
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
NCT02259348 TERMINATED
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
NCT01083706 COMPLETED
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01427881 COMPLETED
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00997243 TERMINATED
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Alison Walker
NCT02835794 WITHDRAWN
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
University of Florida
NCT00923910 COMPLETED
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
National Cancer Institute (NCI)
NCT02200380 TERMINATED
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
NCT01465386 TERMINATED
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center
NCT02159040 TERMINATED
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.
Novartis Pharmaceuticals
NCT01607645 TERMINATED
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
NCT01118013 TERMINATED
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
NCT01993641 COMPLETED
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
Helsinn Healthcare SA
NCT01621477 TERMINATED
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
NCT00475150 COMPLETED
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT01567059 COMPLETED
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT01224496 COMPLETED
Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders
Singapore General Hospital
NCT01810120 COMPLETED
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Mariella Enoc
NCT01709396 SUSPENDED
ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS
Ottawa Hospital Research Institute
NCT01520805 WITHDRAWN
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Cornerstone Pharmaceuticals
NCT02084563 COMPLETED
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
NCT01718379 COMPLETED
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
Groupe Francophone des Myelodysplasies
NCT01085838 COMPLETED
Erlotinib in Higher Risk Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT02147873 TERMINATED
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
TetraLogic Pharmaceuticals
NCT00691938 COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Washington University School of Medicine
NCT01772953 COMPLETED
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
NCT00778375 COMPLETED
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT01652014 WITHDRAWN
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT01674985 COMPLETED
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
NCT01036009 COMPLETED
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
University of California, San Francisco
NCT01099917 COMPLETED
Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?
Memorial Sloan Kettering Cancer Center
NCT02029417 TERMINATED
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT01828346 COMPLETED
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
TetraLogic Pharmaceuticals
NCT01541280 COMPLETED
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Nantes University Hospital
NCT01019317 COMPLETED
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00721214 COMPLETED
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
Virginia Commonwealth University
NCT01413568 COMPLETED
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
NCT01690507 COMPLETED
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Chinese PLA General Hospital
NCT01488565 COMPLETED
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia
Peter MacCallum Cancer Centre, Australia
NCT01338337 COMPLETED
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Asociación Andaluza de Hematología y Hemoterapia
NCT01822691 COMPLETED
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
H. Lee Moffitt Cancer Center and Research Institute
NCT01336712 COMPLETED
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
Northside Hospital, Inc.
NCT01246076 COMPLETED
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Washington University School of Medicine
NCT00731328 COMPLETED
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Asan Medical Center
NCT01880437 TERMINATED
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
Hoffmann-La Roche
NCT01624701 TERMINATED
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
Singapore General Hospital
NCT01211691 SUSPENDED
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Humanigen, Inc.
NCT00954941 COMPLETED
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
NCT00666497 TERMINATED
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
NCT02428686 COMPLETED
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
Groupe Francophone des Myelodysplasies
NCT01488253 TERMINATED
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
The Korean Society of Blood and Marrow Transplantation
NCT01819558 COMPLETED
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Institut Paoli-Calmettes
NCT00977132 TERMINATED
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome
Heinrich-Heine University, Duesseldorf
NCT00656617 COMPLETED
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT01497145 COMPLETED
A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome
Kyowa Kirin Co., Ltd.
NCT00809276 COMPLETED
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01111448 TERMINATED
Temsirolimus in Myelodysplastic Syndrome (MDS)
Technische Universität Dresden
NCT00916045 TERMINATED
Pilot Study of Unrelated Cord Blood Transplantation
King's College Hospital NHS Trust
NCT01010373 SUSPENDED
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
BioMAS Ltd
NCT00897130 COMPLETED
5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)
Università degli Studi di Brescia
NCT00602771 COMPLETED
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01513317 TERMINATED
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Janssen Research & Development, LLC
NCT01333449 TERMINATED
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Singapore General Hospital
NCT01236144 COMPLETED
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Cardiff University
NCT00495547 TERMINATED
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
PETHEMA Foundation
NCT00949117 TERMINATED
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
University of South Florida
NCT01324960 WITHDRAWN
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT00776503 COMPLETED
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
Groupe Francophone des Myelodysplasies
NCT01015352 COMPLETED
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
Groupe Francophone des Myelodysplasies
NCT01063257 COMPLETED
Clofarabine in High Risk Myelodysplastic Syndrome (MDS)
Groupe Francophone des Myelodysplasies
NCT01500161 TERMINATED
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
NCT00782379 COMPLETED
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Northside Hospital, Inc.
NCT01048034 COMPLETED
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Nordic MDS Group
NCT00619099 COMPLETED
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Eisai Inc.
NCT00720850 TERMINATED
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Technische Universität Dresden
NCT00977548 COMPLETED
Erlotinib Study for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
NCT00882102 COMPLETED
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
NCT00744757 COMPLETED
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
Johnson & Johnson Taiwan Ltd
NCT00360672 COMPLETED
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00700011 TERMINATED
Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)
Texas Oncology Cancer Center
NCT00968071 COMPLETED
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00823524 COMPLETED
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
NCT00732316 COMPLETED
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
Asan Medical Center
NCT00570999 WITHDRAWN
Palifermin After Haploidentical PBSCT
European Society for Blood and Marrow Transplantation
NCT00719836 COMPLETED
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
S*BIO
NCT00795548 COMPLETED
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
Heinrich-Heine University, Duesseldorf
NCT00700206 COMPLETED
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Telik
NCT07573111 NOT YET RECRUITING
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
NCT06484062 RECRUITING
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT05088356 ACTIVE NOT RECRUITING
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT03770429 ACTIVE NOT RECRUITING
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
NCT06996119 RECRUITING
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
NCT07270978 RECRUITING
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
University of Virginia
NCT06788509 ENROLLING BY INVITATION
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
NCT07384715 RECRUITING
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
NCT06034470 ACTIVE NOT RECRUITING
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
NCT03560882 ACTIVE NOT RECRUITING
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT05146739 ACTIVE NOT RECRUITING
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT07565220 NOT YET RECRUITING
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Sawa Ito, MD
NCT04953897 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology, Inc.
NCT04953910 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology, Inc.
NCT02890329 ACTIVE NOT RECRUITING
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06195891 RECRUITING
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06247787 RECRUITING
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Children's Oncology Group
NCT07302776 NOT YET RECRUITING
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
NCT03896269 RECRUITING
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT03572764 ACTIVE NOT RECRUITING
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Washington University School of Medicine
NCT06047886 RECRUITING
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT03017820 RECRUITING
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT06656494 RECRUITING
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
NCT06146257 RECRUITING
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics Inc.
NCT04190550 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05473910 RECRUITING
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
NCT06419634 RECRUITING
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
NCT04227847 RECRUITING
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen, a wholly owned subsidiary of Pfizer
NCT07254793 NOT YET RECRUITING
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
NCT06502145 RECRUITING
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
Medical College of Wisconsin
NCT04024761 RECRUITING
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT04279847 ACTIVE NOT RECRUITING
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Incyte Corporation
NCT04980404 ACTIVE NOT RECRUITING
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
NCT07020533 RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT00819546 ACTIVE NOT RECRUITING
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Richard Stone, MD
NCT07107126 RECRUITING
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan, Inc.
NCT03533816 RECRUITING
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
NCT03874052 RECRUITING
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Jennifer Saultz
NCT05636514 RECRUITING
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Clinical Hub for Interventional Research (CHOIR)
NCT06994676 RECRUITING
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Crossbow Therapeutics, Inc.
NCT05292664 RECRUITING
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT06498973 RECRUITING
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04375631 RECRUITING
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT03969446 RECRUITING
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT06543381 RECRUITING
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT07044544 RECRUITING
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07283094 RECRUITING
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Montefiore Medical Center
NCT06846606 ACTIVE NOT RECRUITING
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
NCT03630991 RECRUITING
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
NCT03802695 RECRUITING
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT06616636 RECRUITING
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
M.D. Anderson Cancer Center
NCT06372717 RECRUITING
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
NCT06551584 RECRUITING
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Stanford University
NCT05455294 ACTIVE NOT RECRUITING
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT07321626 RECRUITING
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
First Affiliated Hospital of Zhejiang University
NCT06326463 RECRUITING
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT06359002 ACTIVE NOT RECRUITING
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
NCT07347418 NOT YET RECRUITING
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
University of Colorado, Denver
NCT07347171 RECRUITING
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
NCT05143996 RECRUITING
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cullinan Therapeutics Inc.
NCT07006025 RECRUITING
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Treebough Therapies
NCT05362773 RECRUITING
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT05342584 RECRUITING
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Montefiore Medical Center
NCT02530034 ACTIVE NOT RECRUITING
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03912064 ACTIVE NOT RECRUITING
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT06138587 RECRUITING
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT03613532 ACTIVE NOT RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT04245397 RECRUITING
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Syntrix Biosystems, Inc.
NCT06552416 RECRUITING
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Marker Therapeutics, Inc.
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT04608110 RECRUITING
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Taiho Pharmaceutical Co., Ltd.
NCT03326921 RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT05986240 RECRUITING
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT03113643 RECRUITING
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
NCT06533761 RECRUITING
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Stelexis BioSciences
NCT02494167 ACTIVE NOT RECRUITING
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Baylor College of Medicine
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT06465160 RECRUITING
A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
Minovia Therapeutics Ltd.
NCT06501196 RECRUITING
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT05823571 ACTIVE NOT RECRUITING
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04281199 ACTIVE NOT RECRUITING
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
City of Hope Medical Center
NCT07131085 NOT YET RECRUITING
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Anhui Provincial Hospital
NCT06378437 RECRUITING
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
NCT06357182 RECRUITING
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT03843528 ACTIVE NOT RECRUITING
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT02942290 ACTIVE NOT RECRUITING
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
NCT06670222 RECRUITING
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Groupe Francophone des Myelodysplasies
NCT06287944 RECRUITING
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
NCT05703542 RECRUITING
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Eric Stephen Winer, MD
NCT01494103 ACTIVE NOT RECRUITING
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT00710892 ACTIVE NOT RECRUITING
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT04891757 ACTIVE NOT RECRUITING
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
NCT05139004 ACTIVE NOT RECRUITING
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06594445 RECRUITING
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT04603001 ACTIVE NOT RECRUITING
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT02074839 RECRUITING
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT05320809 ACTIVE NOT RECRUITING
Study of 3D189 in Patients With Hematologic Malignancies
3D Medicines
NCT04013685 ACTIVE NOT RECRUITING
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT02632708 ACTIVE NOT RECRUITING
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Institut de Recherches Internationales Servier
NCT06399640 RECRUITING
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT06820268 RECRUITING
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NovaOnco Therapeutics Co., Ltd.
NCT04250051 ACTIVE NOT RECRUITING
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT04623944 ACTIVE NOT RECRUITING
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta, Inc.
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06034275 RECRUITING
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
NCT03927261 ACTIVE NOT RECRUITING
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Precigen, Inc
NCT04275518 RECRUITING
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Ascentage Pharma Group Inc.
NCT06550713 RECRUITING
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04365179 RECRUITING
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Immune System Key Ltd
NCT06463327 NOT YET RECRUITING
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TC Biopharm
NCT04243785 RECRUITING
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Edgewood Oncology Inc.
NCT02477878 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT04999943 RECRUITING
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Affiliated Hospital to Academy of Military Medical Sciences
NCT04167696 RECRUITING
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Celyad Oncology SA
NCT03816319 SUSPENDED
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT05829226 COMPLETED
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
NCT02211755 COMPLETED
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Cancer Institute (NCI)
NCT05607199 TERMINATED
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT06888323 SUSPENDED
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
NCT06021600 TERMINATED
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
NCT05263271 TERMINATED
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT02333162 SUSPENDED
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
NCT05933070 TERMINATED
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Inmune Bio, Inc.
NCT03494569 SUSPENDED
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT05275439 TERMINATED
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
NCT03232268 COMPLETED
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Institut Paoli-Calmettes
NCT03359460 COMPLETED
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
University of California, Davis
NCT03772925 TERMINATED
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03358719 COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT05170828 WITHDRAWN
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
NCT04915612 COMPLETED
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03600155 COMPLETED
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04328714 TERMINATED
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Edwin Horwitz
NCT06492707 SUSPENDED
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Fred Hutchinson Cancer Center
NCT02381548 TERMINATED
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05787496 TERMINATED
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
NCT05665530 COMPLETED
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
NCT03932643 COMPLETED
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
University of Nebraska
NCT02312102 COMPLETED
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT03573310 COMPLETED
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
NCT06294275 COMPLETED
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
Longbio Pharma
NCT05564650 COMPLETED
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
NCT05534620 COMPLETED
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
NCT01139970 COMPLETED
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
NCT06454409 SUSPENDED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT04937166 TERMINATED
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT04810611 TERMINATED
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Novartis Pharmaceuticals
NCT03940352 TERMINATED
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals
NCT04609826 COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
NCT05168202 TERMINATED
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
NCT05961839 TERMINATED
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
NCT04951778 TERMINATED
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
NCT01385423 COMPLETED
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
NCT04417517 TERMINATED
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
ALX Oncology Inc.
NCT05209152 TERMINATED
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
NCT02446964 COMPLETED
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT02848001 TERMINATED
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
NCT01290302 COMPLETED
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
NCT06572631 WITHDRAWN
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
NCT03915379 COMPLETED
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
NCT03066648 COMPLETED
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis Pharmaceuticals
NCT03286114 TERMINATED
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
NCT03813147 COMPLETED
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT00588991 COMPLETED
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
NCT02936752 COMPLETED
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
National Cancer Institute (NCI)
NCT04638309 TERMINATED
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
NCT04477291 TERMINATED
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
NCT05030675 COMPLETED
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
M.D. Anderson Cancer Center
NCT03939585 WITHDRAWN
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Leland Metheny
NCT02846376 TERMINATED
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Hackensack Meridian Health
NCT03884829 TERMINATED
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
NCT05823480 WITHDRAWN
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
NCT04017546 COMPLETED
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
NCT03814005 COMPLETED
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
NCT03187288 COMPLETED
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
University Health Network, Toronto
NCT04901416 COMPLETED
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
Coeptis Therapeutics
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT01913951 COMPLETED
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Washington University School of Medicine
NCT02181699 TERMINATED
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Kyowa Kirin, Inc.
NCT01588015 COMPLETED
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01684150 COMPLETED
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Epizyme, Inc.
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT04912063 TERMINATED
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
NCT02841540 TERMINATED
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Hemavant Sciences GmbH
NCT05107856 TERMINATED
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
NCT02367456 COMPLETED
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Pfizer
NCT04718844 COMPLETED
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
Silence Therapeutics plc
NCT04439006 COMPLETED
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04361058 WITHDRAWN
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
SCRI Development Innovations, LLC
NCT00697684 COMPLETED
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Beth Israel Deaconess Medical Center
NCT02543879 COMPLETED
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Forma Therapeutics, Inc.
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02782468 COMPLETED
A Study of Pevonedistat in Adult East Asian Participants
Millennium Pharmaceuticals, Inc.
NCT02916979 COMPLETED
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Dartmouth-Hitchcock Medical Center
NCT02649764 COMPLETED
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05456269 WITHDRAWN
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Racura Oncology Ltd
NCT02122081 COMPLETED
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT04402541 COMPLETED
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cleave Therapeutics, Inc.
NCT04443751 COMPLETED
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Jiangsu HengRui Medicine Co., Ltd.
NCT00941109 COMPLETED
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Eisai Inc.
NCT02966782 COMPLETED
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
AbbVie
NCT03465540 TERMINATED
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT04485065 SUSPENDED
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Innovent Biologics (Suzhou) Co. Ltd.
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03746041 COMPLETED
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
University of Rochester
NCT03393611 COMPLETED
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
NCT01700335 COMPLETED
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
SymBio Pharmaceuticals
NCT02014051 COMPLETED
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
SymBio Pharmaceuticals
NCT02783547 WITHDRAWN
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome
SymBio Pharmaceuticals
NCT03495167 COMPLETED
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
SymBio Pharmaceuticals
NCT04543305 COMPLETED
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics
NCT01286038 TERMINATED
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
H. Lee Moffitt Cancer Center and Research Institute
NCT04022785 COMPLETED
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02553941 COMPLETED
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Brian Jonas
NCT01834248 COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT03483324 COMPLETED
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Angiocrine Bioscience
NCT02979366 COMPLETED
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT03787498 COMPLETED
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Opna Bio LLC
NCT01433965 COMPLETED
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
University of California, Davis
NCT03696537 TERMINATED
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Naoyuki G. Saito, M.D., Ph.D.
NCT02083250 COMPLETED
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03459859 COMPLETED
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Justin Watts, MD
NCT03519984 TERMINATED
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
NCT03263637 COMPLETED
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
NCT03516591 COMPLETED
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Amphivena Therapeutics, Inc.
NCT03588936 TERMINATED
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
NCT02319369 TERMINATED
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Daiichi Sankyo
NCT04464889 WITHDRAWN
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
NCT03074006 COMPLETED
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
MedPacto, Inc.
NCT03057990 WITHDRAWN
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
Montefiore Medical Center
NCT03018223 COMPLETED
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
NCT01953692 COMPLETED
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Merck Sharp & Dohme LLC
NCT03555955 COMPLETED
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
NCT01822509 COMPLETED
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT03885947 COMPLETED
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Alla Keyzner
NCT02485535 COMPLETED
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
NCT02129582 COMPLETED
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT00620633 COMPLETED
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT02243124 TERMINATED
A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
Eleos, Inc.
NCT04511975 SUSPENDED
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
Innovent Biologics (Suzhou) Co. Ltd.
NCT01613976 COMPLETED
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Novartis Pharmaceuticals
NCT01643603 TERMINATED
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NCT01300611 TERMINATED
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Tarix Pharmaceuticals
NCT02750995 COMPLETED
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
Daniel El Fassi
NCT02750254 TERMINATED
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT02029950 COMPLETED
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT02786485 WITHDRAWN
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
NCT00809250 COMPLETED
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00916227 COMPLETED
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT01496495 COMPLETED
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00674427 TERMINATED
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
University of Pennsylvania
NCT03807063 WITHDRAWN
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01159028 COMPLETED
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Bio-Path Holdings, Inc.
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT04176653 WITHDRAWN
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
Silence Therapeutics plc
NCT01636609 TERMINATED
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02212561 COMPLETED
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02370888 TERMINATED
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
University of Florida
NCT01629082 COMPLETED
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT02231853 TERMINATED
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Heart, Lung, and Blood Institute (NHLBI)
NCT00973804 TERMINATED
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
National Cancer Institute (NCI)
NCT01300572 COMPLETED
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
Fred Hutchinson Cancer Center
NCT02995655 COMPLETED
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Washington University School of Medicine
NCT02909972 COMPLETED
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Aileron Therapeutics, Inc.
NCT00652626 COMPLETED
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
Celgene
NCT01519011 COMPLETED
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
Celgene
NCT01571648 COMPLETED
A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes
Celgene
NCT00761722 COMPLETED
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
Celgene
NCT02129101 COMPLETED
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
NCT03612739 WITHDRAWN
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT02167958 COMPLETED
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Rafic Farah, MD
NCT02508870 COMPLETED
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hoffmann-La Roche
NCT03735446 TERMINATED
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
NCT02920541 COMPLETED
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT02117219 COMPLETED
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
MedImmune LLC
NCT01463046 COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
University of California, San Francisco
NCT02749708 TERMINATED
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01700751 COMPLETED
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Washington University School of Medicine
NCT02492737 COMPLETED
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Agios Pharmaceuticals, Inc.
NCT02678338 COMPLETED
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
NCT01957644 TERMINATED
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
NCT01634217 COMPLETED
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
NCT02323139 COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Groupe Francophone des Myelodysplasies
NCT02676323 TERMINATED
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02641002 TERMINATED
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Celgene
NCT01342289 COMPLETED
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT02721875 TERMINATED
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
Boehringer Ingelheim
NCT02201329 COMPLETED
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT02226861 COMPLETED
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
NCT02203825 COMPLETED
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Celyad Oncology SA
NCT01757639 COMPLETED
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00875693 COMPLETED
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Weill Medical College of Cornell University
NCT00908167 COMPLETED
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00854646 COMPLETED
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
NCT02308761 COMPLETED
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Hoffmann-La Roche
NCT01207076 TERMINATED
AHN-12 Biodistribution in Advanced Leukemia
Masonic Cancer Center, University of Minnesota
NCT00686556 COMPLETED
Total Marrow Irradiation for Refractory Acute Leukemia
Masonic Cancer Center, University of Minnesota
NCT00725062 TERMINATED
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT00903422 COMPLETED
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
GlaxoSmithKline
NCT01449058 COMPLETED
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
NCT01399840 COMPLETED
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Pfizer
NCT00988715 COMPLETED
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT01169012 COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
UNC Lineberger Comprehensive Cancer Center
NCT00624936 COMPLETED
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
NCT01085656 TERMINATED
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
University of Florida
NCT01130506 COMPLETED
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT01034592 TERMINATED
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Jason Robert Gotlib
NCT01048619 COMPLETED
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Traws Pharma, Inc.
NCT00513474 COMPLETED
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
NCT02564536 WITHDRAWN
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
NCT02000154 COMPLETED
Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
SymBio Pharmaceuticals
NCT01065129 COMPLETED
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
NCT02002936 COMPLETED
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
SymBio Pharmaceuticals
NCT01362036 TERMINATED
Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Tarix Pharmaceuticals
NCT00891592 COMPLETED
Umbilical Cord Blood Transplant for Hematological Malignancies
University of Pennsylvania
NCT01174888 COMPLETED
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Alison Walker
NCT01003678 TERMINATED
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
Roswell Park Cancer Institute
NCT01204164 COMPLETED
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Tragara Pharmaceuticals, Inc.
NCT01075425 COMPLETED
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
NCT01398462 COMPLETED
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
NCT00986804 COMPLETED
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Washington University School of Medicine
NCT00892190 COMPLETED
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
University of Pittsburgh
NCT01260714 TERMINATED
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01908387 TERMINATED
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene Corporation
NCT00800150 TERMINATED
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
NCT01041443 COMPLETED
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
City of Hope Medical Center
NCT00750334 TERMINATED
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
Genzyme, a Sanofi Company
NCT01149915 COMPLETED
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
NCT01390311 COMPLETED
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
Washington University School of Medicine
NCT01152346 COMPLETED
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
Bioniche Pharma USA LLC
NCT01132586 COMPLETED
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00891137 COMPLETED
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
NCT01164163 COMPLETED
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
NCT00858572 COMPLETED
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
NCT00875745 COMPLETED
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University
NCT00640796 COMPLETED
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
St. Jude Children's Research Hospital
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT01068301 COMPLETED
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
NCT00923234 TERMINATED
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
Technische Universität Dresden
NCT00796003 COMPLETED
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Janssen Pharmaceutical K.K.
NCT00911066 COMPLETED
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Millennium Pharmaceuticals, Inc.
NCT01009502 TERMINATED
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Northwestern University
NCT00996359 TERMINATED
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
University of Medicine and Dentistry of New Jersey
NCT00828802 COMPLETED
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
Duke University
NCT00871702 COMPLETED
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Washington University School of Medicine
NCT00807677 COMPLETED
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
NCT01062152 COMPLETED
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Telik
NCT00671697 COMPLETED
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Washington University School of Medicine
NCT01481220 COMPLETED
Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)
Nordic MDS Group
NCT00676728 TERMINATED
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00684008 COMPLETED
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
Cytheris, Inc.
NCT01066468 TERMINATED
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Novartis Pharmaceuticals
NCT00502112 COMPLETED
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Seagen Inc.
NCT03176849 COMPLETED
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
NCT02145026 COMPLETED
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
Hoffmann-La Roche
NCT01201811 COMPLETED
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Celgene
NCT03598582 COMPLETED
Biological Predictive Factors of Response to ESA in Low Risk MDS Patients
Association pour la recherche sur les Affections Malignes en Immunologie Sanguine
NCT01200355 COMPLETED
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT01736540 COMPLETED
An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Novartis Pharmaceuticals
NCT01326845 TERMINATED
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
Novartis Pharmaceuticals
NCT01250951 COMPLETED
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
Novartis Pharmaceuticals
NCT01011283 TERMINATED
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
Eisai Inc.
Full MDS Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only